Sign up Australia
Proactive Investors - Run By Investors For Investors

Medical Australia’s breast pumps gain critical endorsement

Ardo will be the only breast pump endorsed by the ABA.
Medical Australia’s breast pumps gain critical endorsement
The global breast pumps market is rapidly growing

Medical Australia (ASX:MLA) has secured a three-year partnership with the Australian Breastfeeding Association (ABA) in which ABA community groups will now purchase Ardo breast pumps.

Ardo Carum and Calypso breast pumps are manufactured by Medical Australia’s Clements Medical Equipment division and are distributed in Australia and New Zealand as ‘Ardo by Clements’.

ABA is a voluntary organisation founded by six mothers in 1964.

The association has spread to all Australian states and territories to become one of the country’s largest women’s not-for-profit organisations and Australia’s leading authority on breastfeeding.

Under the agreement, Ardo’s Carum (hospital grade) and Calypso (portable pump), which are World Health Organisation (WHO) code compliant, will be the only breast pumps endorsed by the ABA.

The ABA will also actively promote the products through its broad communication network.

Moreover, close to 200 ABA community groups throughout Australia will transition to using Ardo breast pumps.

This is a significant achievement for Medical Australia and follows a rigorous testing process where the ABA established an expert working group to implement the evaluation process and survey.

The Ardo pumps were tested using standardised criteria by mothers with babies of various ages and are expected to greatly assist women with their breastfeeding and expressing requirements.

The global breast pumps market is estimated to grow at a compounded annual growth rate of 8.8% from 2014 to 2020 and reach a value of US$2.6 billion by 2020.



Register here to be notified of future MLA Company articles
View full MLA profile View Profile

Medical Australia Timeline

Related Articles

Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use